Efficacy of Mictalase® After ThuLEP

NACompletedINTERVENTIONAL
Enrollment

111

Participants

Timeline

Start Date

December 1, 2019

Primary Completion Date

February 28, 2021

Study Completion Date

April 30, 2021

Conditions
BPH With Urinary Obstruction With Other Lower Urinary Tract Symptoms
Interventions
DEVICE

Phenolmicin P3 and Bosexil suppository

The suppository we herein investigated includes different active principles, namely: Bosexil®, that is a vegetal extract derived from the resin of the Boswellia serrata, a plant native to India. It has already been published that the Boswellic acids contained show anti-inflammatory and antioxidant properties in a variety of inflammatory diseases whose physio-pathological pathways are shared with those of prostatitis; phenolmicin P3 is a polyphenolic extract derived from beehive propolis, that also demonstrated anti-inflammatory and antioxidant properties in preclinical reports. It has also been reported to have the ability to create a microenvironment hostile to the reproduction of pathogenic bacteria.

Trial Locations (1)

Unknown

San Carlo di Nancy Hospital, Roma

All Listed Sponsors
collaborator

Lampugnani Farmaceutici S.p.A. (Nerviano, Milan, Italy)

UNKNOWN

lead

San Carlo di Nancy Hospital

OTHER

NCT05130918 - Efficacy of Mictalase® After ThuLEP | Biotech Hunter | Biotech Hunter